UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Biologic Markers as Predictors of Clinical Outcome From Systemic Therapy for Primary Operable Breast Cancer

Journal of clinical oncology, 1999-10, Vol.17 (10), p.3058-3063

1999

Volltextzugriff (PDF)

Proliferation Marker Ki-67 in Early Breast Cancer

Journal of clinical oncology, 2005-10, Vol.23 (28), p.7212-7220

2005

Volltextzugriff (PDF)

Neoadjuvant Treatment of Postmenopausal Breast Cancer With Anastrozole, Tamoxifen, or Both in Combination: The Immediate Preoperative Anastrozole, Tamoxifen, or Combined With Tamoxifen (IMPACT) Multicenter Double-Blind Randomized Trial

Journal of clinical oncology, 2005-08, Vol.23 (22), p.5108-5116

2005

Volltextzugriff (PDF)

Retrospective Analysis of Time to Recurrence in the ATAC Trial According to Hormone Receptor Status: An Hypothesis-Generating Study

Journal of clinical oncology, 2005-10, Vol.23 (30), p.7512-7517

2005

Volltextzugriff (PDF)

Molecular Changes in Tamoxifen-Resistant Breast Cancer: Relationship Between Estrogen Receptor, HER-2, and p38 Mitogen-Activated Protein Kinase

Journal of clinical oncology, 2005-04, Vol.23 (11), p.2469-2476

2005

Volltextzugriff (PDF)

Influence of letrozole and anastrozole on total body aromatization and plasma estrogen levels in postmenopausal breast cancer patients evaluated in a randomized, cross-over study

Journal of clinical oncology, 2002-02, Vol.20 (3), p.751-757

2002

Volltextzugriff (PDF)

Biomarker Changes During Neoadjuvant Anastrozole, Tamoxifen, or the Combination: Influence of Hormonal Status and HER-2 in Breast Cancer—A Study from the IMPACT Trialists

Journal of clinical oncology, 2005-04, Vol.23 (11), p.2477-2492

2005

Volltextzugriff (PDF)

Phase II Study of the Efficacy and Tolerability of Two Dosing Regimens of the Farnesyl Transferase Inhibitor, R115777, in Advanced Breast Cancer

Journal of clinical oncology, 2003-07, Vol.21 (13), p.2492-2499

2003

Volltextzugriff (PDF)

Weight change associated with anastrozole and tamoxifen treatment in postmenopausal women with breast cancer or at high risk of developing it

Journal of clinical oncology, 2011-09, Vol.29 (27_suppl), p.165-165

2011

Volltextzugriff (PDF)

Biomarker changes associated with the development of resistance to aromatase inhibitors (AIs) in ER-positive breast cancer

Journal of clinical oncology, 2010-05, Vol.28 (15_suppl), p.1034-1034

2010

Volltextzugriff (PDF)

Comparison of the Systemic and Intratumoral Effects of Tamoxifen and the Aromatase Inhibitor Vorozole in Postmenopausal Patients With Primary Breast Cancer

Journal of clinical oncology, 2002-02, Vol.20 (4), p.1026-1035

2002

Volltextzugriff (PDF)

Polymorphisms of the aromatase gene (CYP19A1) and benefit of aromatase inhibitors (AIs) in metastatic breast cancer (mBC) patients

Journal of clinical oncology, 2011-05, Vol.29 (15_suppl), p.608-608

2011

Volltextzugriff (PDF)

Incidence and predictors of ovarian function recovery (OFR) in exemestane patients with breast cancer (BC) with chemotherapy-induced amenorrhea (CIA) using two estradiol assays

Journal of clinical oncology, 2011-05, Vol.29 (15_suppl), p.521-521

2011

Volltextzugriff (PDF)

Molecular effects of anastrozole (A) and tamoxifen (T) alone and combined (C) in the IMPACT trial of neoadjuvant treatment of primary breast cancer

Journal of clinical oncology, 2004-07, Vol.22 (14_suppl), p.537-537

2004

Volltextzugriff (PDF)

Assessment of lipids and bone-derived resorption products during neoadjuvant therapy with anastrozole (A), v tamoxifen (T), v combination (C) in the IMPACT trial

Journal of clinical oncology, 2004-07, Vol.22 (14_suppl), p.675-675

2004

Volltextzugriff (PDF)

Assessment of lipids and bone-derived resorption products during neoadjuvant therapy with anastrozole (A), v tamoxifen (T), v combination (C) in the IMPACT trial

Journal of clinical oncology, 2004-07, Vol.22 (14_suppl), p.675-675

2004

Volltextzugriff (PDF)

Molecular effects of anastrozole (A) and tamoxifen (T) alone and combined (C) in the IMPACT trial of neoadjuvant treatment of primary breast cancer

Journal of clinical oncology, 2004-07, Vol.22 (14_suppl), p.537-537

2004

Volltextzugriff (PDF)

Recurrence risk of node-negative and ER-positive early-stage breast cancer patients by combining recurrence score, pathologic, and clinical information: A meta-analysis approach

Journal of clinical oncology, 2010-05, Vol.28 (15_suppl), p.509-509

2010

Volltextzugriff (PDF)

Use of gene expression patterns post neoadjuvant chemotherapy to identify a role for the MAPK phosphatase DUSP4 in therapeutic resistance and a stem-like phenotype in basal-like breast cancer (BLBC)

Journal of clinical oncology, 2011-05, Vol.29 (15_suppl), p.10509-10509

2011

Volltextzugriff (PDF)

Phase I study of abiraterone acetate (AA) in patients (pts) with estrogen receptor– (ER) or androgen receptor (AR) –positive advanced breast carcinoma resistant to standard endocrine therapies

Journal of clinical oncology, 2011-05, Vol.29 (15_suppl), p.2525-2525

2011

Volltextzugriff (PDF)

Nuclear NF-kb/p65 expression and response to neoadjuvant chemotherapy in breast cancer

Journal of clinical oncology, 2010-05, Vol.28 (15_suppl), p.611-611

2010

Volltextzugriff (PDF)

Aromatase inhibition and very low dose estradiol add-back: A pilot study for novel breast cancer prevention

Journal of clinical oncology, 2006-06, Vol.24 (18_suppl), p.1014-1014

2006

Volltextzugriff (PDF)

Trial of perioperative endocrine therapy: Individualizing care (POETIC)

Journal of clinical oncology, 2011-05, Vol.29 (15_suppl), p.TPS117-TPS117

2011

Volltextzugriff (PDF)

Prognostic (Px) significance of Ki67 before and after neoadjuvant chemotherapy (CT) in early breast cancer

Journal of clinical oncology, 2007-06, Vol.25 (18_suppl), p.573-573

2007

Volltextzugriff (PDF)

Anti-tumor activity of abiraterone acetate (AA), a CYP17 inhibitor of androgen synthesis, in chemotherapy naive and docetaxel pre-treated castration resistant prostate cancer (CRPC)

Journal of clinical oncology, 2008-05, Vol.26 (15_suppl), p.5005-5005

2008

Volltextzugriff (PDF)

1 – 25 von 69

Suche als RSS-Feed

Aktive Filter

Zeitschrift / SerieJournal Of Clinical Oncology

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(69)
Mit Volltextzugriff
(69)

Publikationsform

Artikel
(69)

Sprache

Englisch
(69)
Japanisch
(18)

Erscheinungsjahr

n.n

Kollektion

EZB-FREE-00999 freely available EZB journals
(69)
WK Lippincott Williams & Wilkins–Connect here FIRST to enable access
(69)
NUS Single-Journal Subscriptions
(69)
IngentaConnect Journals
(34)
Ingenta.com
(34)
MEDLINE
(29)

1 weiteren anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

J Clin Oncol
(1)

Menü

Weitere Dienste

Einstellungen

Biologic Markers as Predictors of Clinical Outcome From Systemic Therapy for Primary Operable Breast Cancer

Proliferation Marker Ki-67 in Early Breast Cancer

Neoadjuvant Treatment of Postmenopausal Breast Cancer With Anastrozole, Tamoxifen, or Both in Combination: The Immediate Preoperative Anastrozole, Tamoxifen, or Combined With Tamoxifen (IMPACT) Multicenter Double-Blind Randomized Trial

Retrospective Analysis of Time to Recurrence in the ATAC Trial According to Hormone Receptor Status: An Hypothesis-Generating Study

Molecular Changes in Tamoxifen-Resistant Breast Cancer: Relationship Between Estrogen Receptor, HER-2, and p38 Mitogen-Activated Protein Kinase

Influence of letrozole and anastrozole on total body aromatization and plasma estrogen levels in postmenopausal breast cancer patients evaluated in a randomized, cross-over study

Biomarker Changes During Neoadjuvant Anastrozole, Tamoxifen, or the Combination: Influence of Hormonal Status and HER-2 in Breast Cancer—A Study from the IMPACT Trialists

Phase II Study of the Efficacy and Tolerability of Two Dosing Regimens of the Farnesyl Transferase Inhibitor, R115777, in Advanced Breast Cancer

Weight change associated with anastrozole and tamoxifen treatment in postmenopausal women with breast cancer or at high risk of developing it

Biomarker changes associated with the development of resistance to aromatase inhibitors (AIs) in ER-positive breast cancer

Comparison of the Systemic and Intratumoral Effects of Tamoxifen and the Aromatase Inhibitor Vorozole in Postmenopausal Patients With Primary Breast Cancer

Polymorphisms of the aromatase gene (CYP19A1) and benefit of aromatase inhibitors (AIs) in metastatic breast cancer (mBC) patients

Incidence and predictors of ovarian function recovery (OFR) in exemestane patients with breast cancer (BC) with chemotherapy-induced amenorrhea (CIA) using two estradiol assays

Molecular effects of anastrozole (A) and tamoxifen (T) alone and combined (C) in the IMPACT trial of neoadjuvant treatment of primary breast cancer

Assessment of lipids and bone-derived resorption products during neoadjuvant therapy with anastrozole (A), v tamoxifen (T), v combination (C) in the IMPACT trial

Assessment of lipids and bone-derived resorption products during neoadjuvant therapy with anastrozole (A), v tamoxifen (T), v combination (C) in the IMPACT trial

Molecular effects of anastrozole (A) and tamoxifen (T) alone and combined (C) in the IMPACT trial of neoadjuvant treatment of primary breast cancer

Recurrence risk of node-negative and ER-positive early-stage breast cancer patients by combining recurrence score, pathologic, and clinical information: A meta-analysis approach

Use of gene expression patterns post neoadjuvant chemotherapy to identify a role for the MAPK phosphatase DUSP4 in therapeutic resistance and a stem-like phenotype in basal-like breast cancer (BLBC)

Phase I study of abiraterone acetate (AA) in patients (pts) with estrogen receptor– (ER) or androgen receptor (AR) –positive advanced breast carcinoma resistant to standard endocrine therapies

Nuclear NF-kb/p65 expression and response to neoadjuvant chemotherapy in breast cancer

Aromatase inhibition and very low dose estradiol add-back: A pilot study for novel breast cancer prevention

Trial of perioperative endocrine therapy: Individualizing care (POETIC)

Prognostic (Px) significance of Ki67 before and after neoadjuvant chemotherapy (CT) in early breast cancer

Anti-tumor activity of abiraterone acetate (AA), a CYP17 inhibitor of androgen synthesis, in chemotherapy naive and docetaxel pre-treated castration resistant prostate cancer (CRPC)

Aktive Filter

Suchergebnisse filtern